Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism

Stock Information for Rezolute Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rezolute Inc.

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Rezolute to Participate in Upcoming Investor Conferences
Rezolute, Inc. Announces Closing of Underwritten Offering
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ("HI")
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.